Pradaxa to be covered by health insurance

Published: 2012-07-31 07:00:00

Updated: 2012-07-31 07:00:00

Pradaxa (dabigatran etexilate), the blood thinning drug by the German pharmaceutical Company Boehringer Ingleheim, has moved closer to get listed in the national health insurance, with the Health Insurance Review and Assessment Service (HIRA) giving the thumbs-up to do so.

The HIRA acknowledge...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK